Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab versus placebo in Japanese adults with active thyroid eye disease
jRCT2031210453Phase 3Completed
- Sponsor
- Horizon Therapeutics
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) and Graves' disease comparing Teprotumumab with Placebo (2 arms). Primary endpoint: Proptosis responder rate at Week 24. Started Nov 2021; status: completed.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)Graves' disease
Beyond the preview
Go deeper on jRCT2031210453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210453.